This article is more than 5 years old. Information may no longer be current.

FDA approves Perrigo generic equivalents for dermatitis treatment

The FDA has given final approval for Perrigo Co.’s abbreviated new drug applications for fluocinolone acetonide scalp oil, 0.01%, and fluocinolone acetonide topical oil, 0.01%, the company announced.

The products are the generic equivalent of Derma-Smoothe/FS Scalp Oil and Derma-Smoothe/FS Body Oil (Hill Dermaceuticals) and are indicated for topical treatment of atopic dermatitis in adults and topical treatment of moderate to severe atopic dermatitis in pediatric patients aged 3 months and older for up to 4 weeks, according to a press release. Perrigo anticipates shipping the products in September.

“This is another example of our Rx team’s commitment to launching difficult-to-manufacture topicals, lotions and foams,” Joseph C. Papa, Perrigo chairman and chief executive office, said in the release.